

Světlana SKUTILOVÁ
University Hospital Brno

DEMENTIA



DEMENTIA - INTRODUCTION

- De (without) - Mens (sense)

WARNING SIGNS

slowly progression, taking minimum a few months

COGNITIVE DISTURBANCE

- (memory, orientation, speech, attention, delusions, hallucination)



■ BEHAVIOUR DISTURBANCE

- (personality, emotion-
apathy, aggression, depression)

■ LOSS OF SELF-SUFFICIENCY

- (employmenttake care about themselves)

- silent epidemic of the 21. century
- illness of the all family – **objectiv anamnesis!**
- 150.000 patients now in the Czech republic
- (10 million inhabitants...)

CLASSIFICATION

Swedish Consensus on Dementia and Dementia diseases

-
- **A.** PRIMARY DEGENERATIVE DEMENTIA
-
- **B.** VASCULAR DEMENTIA
-
- **C.** SECONDARY DEMENTIA

- WHO makes diagnosis of dementia in CZ ?
- Neurologist +psychiatrist +geriatrist
- in cooperation with neuropsychologist

NEUROPSYCHOLOGIC EXAM

- TARGET:
- - examine of all the brain lobes
- The most exact tests for F lobe
- The less exact tests for T lobe
- The least exact test for O+P lobe

ADVANTAGE of psychologic tests

- Standardization (comparison each other)
- Sensitivity (detection of minimum deficit)
- Repeatable (result during time)
- Quantification (score)

Disadvantage of psychologic test

- Absence of neuropsychologist
- Examination takes a few hours
- **Bed – side tests**
- Short, orientational assessment of cognitive function ever by general practitioner or ambulatory specialist

ORIENTATIONAL RULE

- The type of dominant lobe impairment helps us with
- differential diagnosis of dementia kind

F (behavior function) FTD

T....P (memory function) AD

P + O (visually constructive function) DLBD

multiple impairment VD

MMSE /Minimal state examination/

- The most used test (1975)
- WHY??
- **ADVANTAGE:**
 - - quick
 - - easy administration
 - - requirement of Czech insurance company
 - - monitoration of dementia progression

- **DISADVANTAGE:**

- Not enough sufficient for

- - **early** stage of dementia (MMSE oft normal)

- - diagnosis of **FTD** (no examination of F lobe)

- - diagnosis of **DLBD** (no examination of

- O + P lobe)

STAGE OF DEMENTIA according to MMSE (30-0 points)

- Mild 25 - 18 p.
- Medium 17 - 6 p.
- Serious 5 - 0 p.
-
- Standard score 28-30 p.
- ?? IMPORTANCE – therapeutic strategy !

ACE /Addenbrooks cognitive examination/

- SCORE
- Maximum 100 points (MMSE is a part of)
- Less than 82 p.
- : sensitivity of dementia 84%
- : specificity of dementia 100%

MMSE contrary to ACE

■ MMSE



■ 10-15 min



■ -MONITORATION
■ of developed
■ dementia



ACE

25 -30 min

- EARLY dementia
- FTD, DLBD

What a kind of the test CHOOSE?

- **1. ACE:**
 - **Suspicion** of the dementia
 - Expected **another** kind of dementia than AD or VD

- **2. MMSE:**
 - Already developed dementia
 - **Monitoration** of dementia

2. CAUSES OF DEMENTIA

- The causes of dementia : about 60 various diseases

A/ Primary **NEURODEGENERATIVE** Dementia

- **B/VASCULAR** Dementia

- **C/SECONDARY** Dementia attending basic

- **NEUROLOGIC** or **INTERNAL** diagnosis

- (disturbance of metabolism, nutrition, endocrinopathy, toxic brain disturbance)

PRIMARY TARGET

- Exclude SECONDARY Dementia (**TRETABLE**)
- **EVERY!! NEUROIMAGING** (CT, MRI, PET MRI)
- - Blood Tests : blood count, renal/liver biochemistry, vitamine B12, thyroid function tests (Cu + ceruloplasmin, serology HIV + syphilis)
- - CSF (basic, triplet, protein 14-3-3)
- - (EEG)
- - (genetic)

Disturbance IMITATING Dementia

- 1. Minimal cognitive impairment (MCI)
- 10-15% transformation to AD

- 2. DEPRESSION (pseudodementia)
- - therapeutic test with antidepressant

- 3. DELIRIUM
- - sudden starting, fluctuating, duration days
- + quantitative consciousness failure

- 4. Side effects of **FARMAKOTREATMENT**
- in old age
- Anticholinergic (Akineton, tricyclics antidepressant)
- opiates
- hypnotic



A/ PRIMARY DEGENERATIVE DEMENTIA

- HISTOLOGIC CRITERIA:
- 1. **AMYLOIDOPATHIES** - ALZHEIMER'S D.
- Amyloid plaques... **deposits of B amyloid**
- 2. **TAUOPATHIES** - FRONTOTEMPORAL D.
- - CBD, PSP
- Pick bodies **deposits of Tau protein**
/ubiquitin protein/
- 3. **SYNUKLEINOPATHIES** – DLBD, PDD
- Lewy bodies... **deposits of synuklein**

ALZHEIMER'S DISEASE

MOST OFTEN!!

- 60% of all the kinds of dementia
- Preclinic stadium even 15 years
- Neuropsychologic exam : The first sign -
- **DISTURBANCE OF RECENT MEMORY**
- T-P lobe
- HISTOLOGY: AMYLOIDOPATHIES



RISK FACTORS

AGE !!!! 65 years - 5%

- 85 years - 50%

- Low education

- Low intellect and physic activity

- Social izolation

- female gender (3,1 x)

- genetic factors (early onset)

- 1. AD with early onset (to 60 years age) 5%
- - genetic risk faktors ...APO E₄ (alela E₄ for apolipoprotein E)

- 2. AD with late onset (most of patients) !
- -sporadic form

CLINIC DIAGNOSIS OF AD

- 1. PROBABLY
- - disturbance 2 or more cognitive function, progression between 60-90 years, depression, anxiety, delusion, hallucination, emotion instability, incontinency
- Possible neurologic signs (epilepsy, parkinsonism)
-


- 2. DEFINITIVE

- Histologic verification by brain biopsy (post mortem)

NEUROIMAGING AD

- (BRAIN CT):
 - - **atrophy T lobe** (P), extension of lateral ventricles
- BRAIN MRI:
 - - **hippocampal atrophy** (high specificity)


MRI - hippocampal atrophy



BRAIN PET MRI

- i.v.aplication of radioactive isotopes
- - **FDG** (fluorodeoxyglukoza) – decreased glukose metabolism **MEDIOTemporal LOBE**
- (gyrus cinguli, precuneum)...late T-P lobe
- University Hospital Brno 2017

FDG PET MRI



- **AMYLOID** BRAIN PET MRI :
- In vivo detection of amyloid plaques
- Prague 2015 expansive /1800 dollars/


- **ADVANTAGE:** MCI....start of therapy
- early diagnostic
- negative result exclude, no risk
- clinical trials

- **NO:** asymptomatic patient with + genetic
- + familial history

AMYLOID PET MRI

■ NORMAL

PATOLOGY



CSF AD

- TRIPLET : 3 biomarkers, proteins
- BETA-AMYLOID decreased
- TAU-PROTEIN increased
- P/TAU-PROTEIN increased - most exact
- Negative result exclude AD
- University Hospital Brno (2019)

FARMAKOTREATMENT AD

as soon as possible

- SYMPTOMATIC : NO CURE, NO STOP
- **BUT SLOW DOWN**
- **A/** ACETYLCHOLINESTERASE INHIBITORS
- I: Mild and medium stage of AD (MMSE 25-13)
-
- - Donepezil 10mg 1x1
- - Rivastigmin 6mg 2x1 (9,5 mg patch 1x1)
- - Galantamin

Side effects: impaired digestion, parkinsonism

■

- **B/** MEMANTIN – influence on NMDA receptors
- Medium stage of AD (MMSE 17-6)

- **A+B/** DUAL THERAPY (MMSE 17-13)

- Mild stadium .. Memory Late stadium... Behaviour

- DO NOT Prescribe : nootropics, vasodilators
- Parallel therapy !!: cognitive training
- physical training
- (only to swallow a pill is insufficiently)
- We have got yet no new drug since 2004
- New trials : biologic therapy - monoclonal antibody against amyloid

TREATMENT of DEPRESSION + ANXIETY:

SSRI, SNRI BZD

- cave tricyklics (AMT, Prothiaden) – anticholinergic side effect
- TREATMENT PSYCHOTIC SYMPTOMS:
- Neuroleptics

DLBD –difusse Lewy body disease

- HISTOLOGY: SYNUKLEINOPATHIES

20% of dementia! underdiagnosed

HISTOPATOLOGY: Lewy bodies (brain stem, limbic cortex, neocortex T-F


DAT scan – asym. hypofunction in striatum

PET MRI – sym cortical hypoperfusion T-P-O


Neuropsychologic exam: vizuokonstruktive dysfunction T-P-O

Dopaminergic FP-CIT SPECT Imaging


Case 1




Case 2



Case 3



Case 4



AD

DLB

CLINICAL F.: fluctuate cognitive disturbance
visual hallucination
parkinsonism

TREATMENT:

- CAVE neuroleptic hypersensitivity (rapid deterioration of parkinsonism)
- Only atypic neuroleptic
- Acetylcholinesterase inhibitors
- L-Dopa in early stadium

FTD – FRONTOTEMPORAL DEMENTIA

Pick's disease

- HISTOLOGY: TAUOPATHIES
(ubiquitinopathies)
- Neuropsychologic exam. : 1. SYMPTOM –
■ BEHAVIOUR OR LANGUAGE DISTURBANCE
■ F + T lobe
- YOUNGER AGE of onset - (45 -65)
- FAMILIAR OCCURENCE (30-50%)
- RAPIDLY PROGRESSION

VARIANTS

- 1. BEHAVIOURAL (Frontal) -55%
- 2. LANGUAGE (PPA)
- And combination of both

1. FRONTAL VARIANT

- **DOMINANT** symptoms:
- **Early change of behaviour** (perseverative, stereotyp)
- Early change of personality
- Early emotional changes (apathy, verbal or physical impulsivity)

- LATE somatic signs :
- Parkinsonism, MND (10-15 %)

- NEUROIMAGING (MRI, PET MRI) :
 - sym atrophy F + front T lobe
- TREATMENT :
- Deficit of serotonin and dopamin transmitter system
 - - **SSRI** (Triticco)
 - - atypic neuroleptic
 - (cognitiv drugs rather no)
 -


2. PPA primary progressive aphasia

- Subtypes: non- fluent aphasia
- semantic
- logopenic


DOMINANT signs: **APHASIA**

- NEUROIMAGING: asym atrophy T lobe (dominant)
- TREATMENT : Logopedics


Frontotemporal
Dementia
(FTD)



Semantic
Dementia
(SD)



Progressive
Non-Fluent
Aphasia
(PNFA)



B/VASCULAR DEMENTIA

- - 20% of dementia
- - after stroke 5x higher risk of onset
- - men more disabled than women

- - diagnosis is problematic, differentiation of AD often only histologic, oft mixed dementia (AD + VD)

DIAGNOSTIC

- Brain MRI (CT)
- Neuropsychologic exam.: more than 1 lobe is
 - impaired
- SONO cerebral vessels
- CSF: biomarkers negativ

VARIANTS OF VD

- 1. D. due to mikroangiopathy (90% because of HT)
- - Binswanger's disease (subcortical leukoencefalopathy)


- 2. D. due to strategic lokalized infarct (F, T)

- 3. Multiinfarct D. (multiply small and large infarcts)

- 4. D. due to difusse hypoxic-ischemic encefalopathy (KPR)

- (5.) D. familial : AMYLOID angiopathy (frequent stroke)
CADASIL (AD, mutation on 19. chromozom)
- young age, migraine, skin biopsy





TREATMENT VD

- Primary and secondary PREVENTION of cerebrovascular disease
- Acetylcholinesterase inhibitors
- Memantin
- DO NOT Prescribe : nootropics, vasodilatans

MIXED DEMENTIA

- *Very often!*
- - Dominant AD + vascular changes
- - Dominant VD + alzheimer changes
-

C/SECONDARY DEMENTIA

- 1. Following BASIC NEUROLOGIC DG:
 - Normal pressure hydrocephalus
 - Brain tumors
 - Craniocerebral injury – chronic SDHematoma
 - Epilepsy
 - Neuroinfection - JCD, neurosyphilis, AIDS
 - SM late stadium
 - Huntington's disease
 - Wilson's disease

Jakob- Creutzfeld disease



- Prion disease
- Incidence 1-2 per million
- 100% mortality
- Incubation time more than 10 years
- The most infectious tissues: BRAIN!
- - cerebral dura, cornea, blood?
- RISK: - Transplant from diseased
- (from 2007 mandatory testing cornea donor)
- - NCH operation (contaminated instrument)
- Disinfectant, UV radiation – DO NOT DESTROY

CLINICAL FEATURES

- Rapidly progressive dementia
 - Cerebellar or visual signs (ataxia)
 - Extraparamidal signs (myoclonus)
 - Pyramidal signs
 - Akinetic mutism
-
- AUTOPSY MANDATORY

DIAGNOSTIC

- EEG - periodic sharp wave complexes
- CSF: 14-3-3 protein detection
- Brain MRI: high signal abnormalities in caudate nucleus + putamen
- NO TREATMENT

A**B**

VARIANTS

- 1. SPORADIC 85%
 - 50-70 years
 - Duration 6 months
- 2. GENETIC (mutation) 10-15%
 -
- 3. NEW variant (infectious) 2-3%
 - 19-39 years
 - Duration 1-1,5 years
 - Due to consumption of infectious animal (BSP)

Other (rare) prion diseases

- KURU (kanibalism, Papua N. Guinea)
- FFI Fatal familial insomnia
 - (+ dementia)
- Gerstman-Straussler-Scheiner d.
 - (dementia)

- 2. Following BASIC INTERNAL DG:
- Hepatal encephalopathy
- Renal (uremic) encefalopathy
- Endocrinopathy (hypothyreodism)
- Deficiency B₁₂, B₁, B₆, folat acid
- Alcohol abuse